Literature DB >> 22718671

Extract of valerian root (Valeriana officinalis L.) vs. placebo in treatment of obsessive-compulsive disorder: a randomized double-blind study.

Siroos Pakseresht1, Hatam Boostani, Mehdi Sayyah.   

Abstract

OBJECTIVE: Obsessive-Compulsive Disorder (OCD) is a common neuropsychiatric condition. Many herbs with psychotropic effects exist which can have fewer side effects compared to more conventional medications. Valeriana Officinalis L. is a well-known medicinal plant with a long history of usage in the world with an effect on GABA. This plant is reported to be safe on humans. Our objective in this study was to compare the efficacy of the extract of Valeriana Officinalis L. with placebo in the treatment of OCD.
METHODS: The study was an 8-week pilot double-blind randomized trial. Thirty-one adult outpatients who met the DSM-IV-TR criteria for OCD based on the structured clinical interview participated in the trial. In this double-blind and randomized trial, patients were randomly assigned to receive either capsule of the extract (765 mg/day) or placebo (30 mg/day) for 8 weeks.
RESULTS: The results showed significant difference between the extract and placebo in the end of treatment (P=0.000). Somnolence was the only significant difference between the two groups in terms of observed side effects (P=0.02).
CONCLUSION: The results suggest that Valeriana Officinalis L. has some antiobsessive and compulsive effects. However, further studies are needed to confirm these findings. Psychiatrists often find that many patients cannot tolerate the side effects of psychiatry medicine Valeriana Officinalis L. is a well-known medicinal plant with a long history of usage in world with effect on GABA.The results showed significant difference between the extract and placebo in the treatment of OCD. There was also no significant difference between the two groups in terms of observed side effects.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22718671     DOI: 10.2202/1553-3840.1465

Source DB:  PubMed          Journal:  J Complement Integr Med        ISSN: 1553-3840


  4 in total

Review 1.  Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.

Authors:  Martin A Katzman; Pierre Bleau; Pierre Blier; Pratap Chokka; Kevin Kjernisted; Michael Van Ameringen; Martin M Antony; Stéphane Bouchard; Alain Brunet; Martine Flament; Sophie Grigoriadis; Sandra Mendlowitz; Kieron O'Connor; Kiran Rabheru; Peggy M A Richter; Melisa Robichaud; John R Walker
Journal:  BMC Psychiatry       Date:  2014-07-02       Impact factor: 3.630

Review 2.  The potential of Valeriana as a traditional Chinese medicine: traditional clinical applications, bioactivities, and phytochemistry.

Authors:  Jianchun Li; Xiaoliang Li; Changfu Wang; Manli Zhang; Minhui Ye; Qiuhong Wang
Journal:  Front Pharmacol       Date:  2022-09-21       Impact factor: 5.988

3.  Effects of Atorvastatin on Negative Sign in Chronic Schizophrenia: a Double Blind Clinical Trial.

Authors:  Mehdi Sayyah; Hatam Boostani; Mitra Ashrafpoori; Siroos Pakseresht
Journal:  Iran J Pharm Res       Date:  2015       Impact factor: 1.696

Review 4.  Placebo Effect in Obsessive-Compulsive Disorder (OCD). Placebo Response and Placebo Responders in OCD: The Trend Over Time.

Authors:  Georgios D Kotzalidis; Antonio Del Casale; Maurizio Simmaco; Lucia Pancheri; Roberto Brugnoli; Marco Paolini; Ida Gualtieri; Stefano Ferracuti; Valeria Savoja; Ilaria Cuomo; Lavinia De Chiara; Alessio Mosca; Gabriele Sani; Paolo Girardi; Maurizio Pompili; Chiara Rapinesi
Journal:  Curr Neuropharmacol       Date:  2019       Impact factor: 7.363

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.